Retatrutide
Retatrutide is Eli Lilly’s investigational triple agonist (GLP-1/GIP/glucagon) in late-stage trials for obesity — not FDA-approved, and therefore not something any compliant program can offer, despite heavy search demand.
- Triple agonist: GLP-1 + GIP + glucagon receptors
- Investigational — phase 3, no FDA approval
- No lawful supply; gray-market product is unregulated API
- Compliant posture: honest content now, catalog-ready later
What it is and where it stands
Retatrutide adds glucagon-receptor activity to the dual-agonist mechanism, and its phase 2 results — average weight reduction beyond anything approved — made it the most anticipated candidate in the category. It remains investigational: phase 3 trials ongoing, no FDA approval, no lawful commercial supply. Any timeline you read is a projection.
The compliance point operators actually need
Search demand for retatrutide is enormous, and a gray market of research-use-only powder sells into it. For a legitimate program the line is absolute: an unapproved drug cannot be prescribed, compounded, or sold — offering “retatrutide” today means sourcing unregulated API outside any lawful channel, which is the exact pattern that ends companies and licenses. The compliant play is content and readiness: capture the search interest honestly (what it is, where trials stand), and be structurally able to add it quickly if approval lands.
Where it sits in the pipeline
Phase 2 results published in 2023 showed roughly 24% average weight reduction at 48 weeks on the top dose — beyond anything approved, with the caveat that phase 2 populations are small. The TRIUMPH phase 3 program is running across obesity and related conditions. Between here and a launch sit trial completion, FDA review, approval, manufacturing scale, and channel build-out — years of steps, each with its own uncertainty.
Status check
| Question | Answer today |
|---|---|
| FDA status | Investigational — phase 3 trials ongoing |
| Lawful supply | None outside Lilly’s trials |
| Compounding pathway | None — unapproved drugs have no compounding basis |
| What programs can do | Publish honest content, capture interest as information, stay catalog-ready |
The branded market it would enter
Retatrutide has no brand name yet — it is a pipeline molecule. If approved, it would join a branded incretin market that today looks like this:
| Brand | Molecule | Maker | Position |
|---|---|---|---|
| Wegovy | semaglutide (GLP-1) | Novo Nordisk | The category-defining weight brand |
| Zepbound | tirzepatide (GLP-1/GIP) | Eli Lilly | The current efficacy benchmark |
| Saxenda | liraglutide (GLP-1) | Novo Nordisk | The earlier daily-injection option |
| (unnamed) | retatrutide (triple) | Eli Lilly | Phase 3 — would enter as the next benchmark |
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Can any program legally offer retatrutide?
No. It is unapproved and outside every lawful prescribing and compounding pathway. Anyone selling it is sourcing unregulated material.
When will retatrutide be approved?
Unknown — phase 3 trials are ongoing and approval timelines are projections. Treat any confident date as marketing.
Why does it matter to programs today?
The search volume is real and growing. Honest educational content captures that demand compliantly and positions a program to move when the regulatory status changes.